See this before the rush for the exits begins
A note from our friends at Weiss Ratings(ad) Dear Reader, A financial crisis usually doesn’t begin with one company defaulting…
Vir Biotechnology Has a Pivotal Win. Now It Needs to Beat Two Rivals to Market.
A clean Phase 3 result puts Vir’s hepatitis delta drug on the path to a mid-2027 FDA filing, but Gilead is already approved and Mirum is right behind.
Applied Materials Is Down 55% and Never Earned More. Something Has to Give Thursday.
Applied Materials has never reported better numbers. Its stock has rarely looked worse. That gap closes Thursday. Sponsored NASA Is…
Datadog Beat Estimates by a Wide Margin. The Stock Fell 14% Anyway.
One undisclosed AI customer cut usage to its minimum commitment, and Wall Street punished the whole business for it.
Socialists win big… Dr. Ron Paul warns what comes next
A note from our friends at MarketWise(ad) Dear Reader, The Democratic Socialists won big at the polls this election cycle.…
CRISPR and Lilly Walk Into the Same 75-Minute Window Tomorrow
Tomorrow morning in Chicago, the American Heart Association’s LBS.05 session opens at 8:00 a.m. CT and closes at 9:15 a.m.…
The 10-Year Auction and CPI Land on the Same Tuesday
With $42 billion of notes to sell and inflation data due at 8:30 that morning, what happens in that one session will tell investors more about demand for US debt than any single auction this year.
Berkshire Just Revealed Its Q3 Cash. The Number That Matters Isn’t Profit.
With $359.2B of cash and T-bills at June 30 and Taylor Morrison closed, what buybacks say matters more than headline EPS.
Why the safest income stream doesn’t show up on Wall Street
A note from our friends at Eagle Publishing(ad) Dear Reader, Todd Phillips has spent 30 years studying safe-money income. And…
A 7.18% Mortgage With Another Rate Hike Coming Changes the Math on Housing
With December hike odds near 80% and the 10-year yield above 4.8%, homebuyers and homebuilder investors face a decision point that will not wait.